2 domains / 4 areas / 2 specializations
Sheba Medical Center
Data updated
Israel's largest hospital and a major academic medical center affiliated with Tel Aviv University. A key site for MDMA-assisted psychotherapy trials through MAPS Israel and other research programs, as well as ketamine studies for treatment-resistant depression.
Academic Research
0 papersPublished Papers
0
Trial Involvement
10
Distinct Focus Topics
0
Latest Publication
Unknown
Entity type: Research Centre / Institute
Clinical Care Delivery Snapshot
Health Systems & HospitalsProvider Model
Health System / Hospital Program
Organization Status
Unknown
Psychedelic Services
Unknown
Service Coverage
Global
Service Profile
Care Settings
Payer Models
Non-Psychedelic Service Mix
Unknown
Care Delivery Notes
Backfilled profile for existing L2 clinical care delivery stakeholder.
Quick Facts
- Type
- Other
- HQ
- Israel
- Website
- Visit
Research Landscape
What the 10 registered trials Sheba Medical Center sponsors or participates in look like when you line them up. Counts come from Blossom’s trial records as of July 2026.
How fast is Sheba Medical Center research growing?
SourcedRegistered trials by recorded study-start year; 1 earlier trial began before 2012. Click a year for the running total.
Don't read as total research effort: only registered trials with a recorded start date are counted (10 of 10 tracked). Recent years under-count because of registration lag; striped bars are still filling in or are planned starts.
What's live right now, and what stopped?
SourcedRegistry status of all 10 Sheba Medical Center trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Which conditions does Sheba Medical Center run trials on?
SourcedTrials per primary indication. Orange marks the largest research focus.
Don't read shares as adding to 100%: a trial with several primary indications counts once per indication. Trial volume signals research attention, not evidence quality.